HEPA (Hepion Pharmaceuticals) Shareholder Yield % : 50.79% (As of Mar. 2026)


What is Hepion Pharmaceuticals Shareholder Yield %?

Hepion Pharmaceuticals HEPA +39.50% Shareholder Yield % is 50.79% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 1,299 Biotechnology companies, Hepion Pharmaceuticals ranks better than 99% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Hepion Pharmaceuticals's Shareholder Yield % was 50.79%.


Hepion Pharmaceuticals  (OTCPK:HEPA) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Hepion Pharmaceuticals Shareholder Yield % Related Terms


Hepion Pharmaceuticals Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals Shareholder Yield % Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.43 1.38 -0.51 -111.36 153.73

Hepion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -248.47 -1,109.16 -1,602.84 153.73 187.53

HEPA vs AXIM, ZVSA, ISCO: Shareholder Yield % Comparison

For the Biotechnology subindustry, Hepion Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Shareholder Yield % falls into.



Hepion Pharmaceuticals Shareholder Yield % Calculation

Hepion Pharmaceuticals's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+187.53 %
=187.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 50.79% mean?
Hepion Pharmaceuticals (HEPA) has a Shareholder Yield % of 50.79% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Hepion Pharmaceuticals and its competitors. According to the industry distribution chart, Hepion Pharmaceuticals ranks #13 out of 1299 companies in the Biotechnology industry, placing it in the top 1%.
Is Hepion Pharmaceuticals' Shareholder Yield % too high?
Hepion Pharmaceuticals' current Shareholder Yield % is 50.79%. Based on the distribution chart, Hepion Pharmaceuticals ranks #13 out of 1299 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Hepion Pharmaceuticals' Shareholder Yield % compare to AXIM and ZVSA?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #13 out of 1299 companies for Shareholder Yield %. This places Hepion Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current Shareholder Yield % is 50.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current Shareholder Yield % of 50.79%. The current Shareholder Yield % is 50.79%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current Shareholder Yield % is 50.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.